Abstract B085: Development of a Translational Manufacturing Strategy for a Novel CD4+ CD26+ mesoCAR T Cell Product for Pancreatic Ductal Adenocarcinoma Patients
The emergence of KRAS inhibitors is reshaping the therapeutic landscape of pancreatic ductal adenocarcinoma (PDAC). Yet responses are seldom durable, and relapse is inevitable, highlighting the ongoing need for aggressive therapeutic strategies. PDAC also remains unresponsive to adoptive T cell therapies (ACT), highl...